Former India opener Krishnamachari Srikkanth lashed out at all-rounder Nitish Reddy, slamming his bowling quality. Reddy, who made his debut in October last year for India, rose to fame after scoring ...

Former India captain and ex–chief selector Krishnamachari Srikkanth has launched another sharp critique of India’s selection policies, this time targeting young cricketer Nitish Kumar Reddy, ...

Dr Reddy’s Laboratories lost Rs 2.16 crore to fraudsters who infiltrated an email thread and rerouted a payment to a fake account. Hackers impersonated Group Pharmaceuticals officials, leading Dr ...

Police said an investigation is underway to trace the culprits and recover the defrauded amount. In a major case of cyber fraud, a sum of Rs 2.16 crore has been siphoned off after fraudsters hacked ...

In a major case of corporate cyber fraud, Dr. Reddy’s Laboratories Ltd. has reportedly lost Rs 2.16 crore after hackers impersonated a company executive and diverted funds meant for another firm, ...

Revanth Reddy had responded to criticism on the induction of Mohammad Azharuddin into the cabinet. Telangana BJP President N Ramchander Rao on Thursday hit out at Chief Minister A Revanth Reddy for ...

India pacer Arundhati Reddy on Thursday landed in Hyderabad after a victorious Women’s ODI World Cup campaign, with friends and ecstatic fans making a beeline to welcome her both at the Rajiv Gandhi ...

Generic drugmaker Dr. Reddy’s Laboratories’ plans to rollout the weight-loss drug Semaglutide in the injectable form in Canada is likely to take more time than expected, with Pharmaceutical Drugs ...

Shares of Dr. Reddy's Laboratories fell over 4% in early trading on Thursday, October 30, after the approval for its Semaglutide injection was delayed. The company has received the Notice of ...

https://www.thehindubusinessline.com/markets/buzzing-stocks-today-dr-reddys-likely-under-pressure-concor-samvardhana-motherson-sharda-motor-gain-focus/article70219579 ...

The American Depositary Receipts of Dr. Reddy's Laboratories Ltd. fell 9.69% to $13.19 in New York on Wednesday after the company’s plan to launch a generic version of a popular weight-loss drug in ...